Hypoxia-inducible factor-1α protects cervical carcinoma cells from apoptosis induced by radiation via modulation of vascular endothelial growth factor and p53 under hypoxia

Medical Science Monitor

Volumn 21, Issue , 2015, Pages 318-325

  Fu, Zhichao ^a   Cheng, Huihua ^a   Chen, Dongsheng ^a   Wang, Fengmei ^a  

^a FUZHOU GENERAL HOSPITAL   (China)

Author keywords

Abnormalities; Apoptosis; Endocrine land Derived; Genes; P53; Radiation Induced; Vascular Endothelial Growth Factor

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; OLIGONUCLEOTIDE; PROTEIN P53; SENSE OLIGODEOXYNUCLEOTIDE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN; HIF1A PROTEIN, HUMAN; TP53 PROTEIN, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANGIOGENESIS; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RADIOTHERAPY; CARCINOMA CELL; CELL PROLIFERATION ASSAY; CELL PROTECTION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HYPOXIA; IN VIVO STUDY; MODULATION; MOUSE; MTT ASSAY; NONHUMAN; RADIATION DOSE; RADIOSENSITIVITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TUMOR GROWTH; TUMOR VOLUME; UTERINE CERVIX CARCINOMA; WESTERN BLOTTING; X RAY; ANIMAL; ANOXIA; BAGG ALBINO MOUSE; CARCINOMA; CHEMISTRY; DISEASE COURSE; HELA CELL LINE; METABOLISM; UTERINE CERVIX TUMOR;

ANIMALS; ANOXIA; APOPTOSIS; CARCINOMA; DISEASE PROGRESSION; FEMALE; FLOW CYTOMETRY; HELA CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MICE, INBRED BALB C; OLIGONUCLEOTIDES; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEIN P53; UTERINE CERVICAL NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; X-RAYS;

EID: 84921915352     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.893265     Document Type: Article

References (24)

1. Luczak MW, Roszak A, Pawlik P et al: Increased expression of HIF-1A and its implication in the hypoxia pathway in primary advanced uterine cervical carcinoma. Oncol Rep, 2011; 26: 1259–64
2. Moeller BJ, Dewhirst MW: HIF-1 and tumour radiosensitivity. Br J Cancer, 2006; 95: 1–5
3. Wachsberger P, Burd R, Dicker AP: Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res, 2003; 9: 1957–71
4. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell, 1997; 88: 323–31
5. Graeber TG, Osmanian C, Jacks T et al: Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature, 1996; 379: 88–91
6. Yan SX, Luo XM, Zhou SH et al: Effect of antisense oligodeoxynucleotides glucose transporter-1 on enhancement of radiosensitivity of laryngeal carcinoma. Int J Med Sci, 2013; 10: 1375–86
7. Ravi R, Mookerjee B, Bhujwalla ZM et al:R egulation of tumor angiogenesis by p53- induced degradation of hypoxia-inducible factor 1alpha, Genes Dev, 2000; 14: 34–44
8. Xing D, Bonanno JA: Hypoxia preconditioning protection of corneal stromal cells requires HIF1alpha but not VEGF. Mol Vis, 2009; 15: 1020–27
9. Semenza GL: O2-regulated gene expression: transcriptional control of ardiorespiratory physiology by HIF-1, J Appl Physiol (1985), 2004; 96: 1173–77; discussion 1170–72
10. Semenza GL: Angiogenesis in ischemic and neoplastic disorders. Annu Rev Med, 2003; 54: 17–28
11. Kelly BD, Hackett SF, Hirota K et al: Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ Res, 2003; 93: 1074–81
12. Seong J: Challenge and hope in radiotherapy of hepatocellular carcinoma. Yonsei Med J, 2009; 50: 601–12
13. Bertout JA, Patel SA, Simon MC: The impact of O2 availability on human cancer. Nat Rev Cancer, 2008; 8: 967–75
14. Harrison LB, Chadha M, Hill RJ et al: Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist, 2002; 7: 492–508
15. Vordermark D, Katzer A, Baier K et al: Cell type-specific association of hypoxia-inducible factor-1 alpha (HIF-1 alpha) protein accumulation and radiobiologic tumor hypoxia, Int J Radiat Oncol Biol Phys, 2004; 58: 1242–50
16. Shukla D, Saxena S, Purushothaman J et al: Bansal, Hypoxic preconditioning with cobalt ameliorates hypobaric hypoxia induced pulmonary edema in rat. Eur J Pharmacol, 2011; 656: 101–9
17. Borenstein X, Fiszman GL, Blidner A et a: Functional changes in murine mammary cancer cells elicited by CoCl2-induced hypoxia. Nitric Oxide, 2010; 23: 234–41
18. Zou Y, Cheng C, Omura-Minamisawa M et al: The suppression of hypoxiainducible factor and vascular endothelial growth factor by siRNA does not affect the radiation sensitivity of multicellular tumor spheroids. J Radiat Res, 2010; 51: 47–55
19. Ryan HE, Poloni M, McNulty W et al: Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res, 2000; 60: 4010–15
20. Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer, 2003; 3: 721–32
21. Kawanaka T, Kubo A, Ikushima H et al: Prognostic significance of HIF-2alpha expression on tumor infiltrating macrophages in patients with uterine cervical cancer undergoing radiotherapy. J Med Invest, 2008; 55: 78–86
22. Moeller BJ, Dreher MR, Rabbani ZN et al: Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell, 2005; 8: 99–110
23. Bertout JA, Majmundar AJ, Gordan JD et al: HIF2alpha inhibition promotes p53 pathway activity, tumor cell death, and radiation responses. Proc Natl Acad Sci USA, 2009; 106: 14391–96
24. Sowter HM, Raval R, Moore J et al: Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. Cancer Res, 2003; 63: 6130–34